[2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-(2-(1-piperidinyl)ethoxy]phenyl]methanone | 170847-38-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: [2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-(2-(1-piperidinyl)ethoxy]phenyl]methanone
• 英文别名: 2-(4-methoxyphenyl)-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-methoxybenzofuran；2-(4-methoxyphenyl)-3-[4-[2-(piperid-1-yl)ethoxy]benzoyl]-6-methoxybenzofuran；[6-methoxy-2-(4-methoxyphenyl)-1-benzofuran-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• CAS: 170847-38-8
• 化学式: C₃₀H₃₁NO₅
• 分子量: 485.58
• InChiKey: JCDOLTDJNBOLLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-(2-(1-piperidinyl)ethoxy]phenyl]methanone 生成 [2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanol
  参考文献：
  名称：

  Benzofuran compounds, compositions, and methods

  摘要：

  本发明提供了一种新颖的化合物，其化学式为：其中Ra为—OH或—O—(C1-C4烷基)；R1a为—OH或—O—(C1-C4烷基)；n为2或3；R2和R3各自独立地为：—C1-C4烷基，或结合形成1-哌啶基，1-吡咯基，1-吡咯基，带有一个或两个甲基的4-吗啉基或1-己亚甲基亚胺基；或其药学上可接受的盐。

  公开号：

  US06407243B1
• 作为产物：
  描述：

  1-(2-氯乙基)哌啶 、 (4-Hydroxyphenyl)<6-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl>methanone 在 potassium carbonate 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 以11.4 g (84%)的产率得到[2-(4-Methoxyphenyl)-6-methoxybenzofuran-3-yl][4-(2-(1-piperidinyl)ethoxy]phenyl]methanone
  参考文献：
  名称：

  Heterocyclic neuropeptide Y receptor antagonists

  摘要：

  这项发明提供了治疗或预防与神经肽Y过多相关病症的方法，这些方法包括给予一个或多个取代苯并呋喃、苯并噻吩或吲哚的方法。

  公开号：

  US05663192A1

文献信息

• Heterocyclic neuropeptide Y receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US05663192A1

  公开（公告）日：1997-09-02

  This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

  这项发明提供了治疗或预防与神经肽Y过多相关病症的方法，这些方法包括给予一个或多个取代苯并呋喃、苯并噻吩或吲哚的方法。
• Methods of treating neuropeptide Y-associated conditions
  申请人：Eli Lilly and Company

  公开号：US06221838B1

  公开（公告）日：2001-04-24

  This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

  本发明描述了治疗与神经肽Y过量相关的疾病的方法，包括给予肥胖蛋白的类似物。本发明进一步描述了治疗与神经肽Y过量相关的疾病的方法，包括给予肥胖蛋白的类似物和神经肽Y拮抗剂的组合。本发明证明肥胖蛋白通过减少下丘脑产生神经肽Y的作用。
• Methods for treating resistant tumors
  申请人：Eli Lilly and Company

  公开号：US06124311A1

  公开（公告）日：2000-09-26

  The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

  本发明提供了治疗多药耐药性肿瘤的方法，通过给需要治疗的哺乳动物使用取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘。本发明还提供了治疗哺乳动物肿瘤的方法，包括向需要该治疗的哺乳动物注射取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘与肿瘤溶解剂联合使用。
• Methods of treating nueropeptide Y-associated conditions
  申请人：Eli Lilly and Company

  公开号：US05972888A1

  公开（公告）日：1999-10-26

  This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

  该发明描述了一种治疗与神经肽Y过量相关的病症的方法，包括给予一种肥胖蛋白质。该发明还描述了一种治疗与神经肽Y过量相关的病症的方法，包括联合给予一种肥胖蛋白质和神经肽Y拮抗剂。该发明证明了肥胖蛋白质通过减少下丘脑产生神经肽Y的作用。
• Bicyclic bradykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0707852A2

  公开（公告）日：1996-04-24

  This invention also provides methods for treating or preventing conditions associated with an excess of bradykinins which methods comprise administration of one or more of the substituted indoles, benzofurans, or benzothiophenes described in this invention.

  本发明还提供了治疗或预防与缓激肽过量有关的疾病的方法，这些方法包括施用一种或多种本发明所述的取代吲哚、苯并呋喃或苯并噻吩。